Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance

Abstract excerpt

Poly-ADP-ribose polymerase (PARP) inhibitors (PARPi) have shown great promise for treating BRCA-deficient tumors. However, over 40% of BRCA-deficient patients fail to respond to PARPi. Here, we report that thioparib, a next-generation PARPi with high affinity against multiple PARPs, including PARP1, PARP2, and PARP7, displays high antitumor activities against PARPi-sensitive and -resistant cells with homologous...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cell death mechanisms and regulation
• Share to DNA Repair Mechanisms
• Share to PARP inhibition in cancer therapy